4OCW

Crystal structure of human Fab CAP256-VRC26.06, a potent V1V2-directed HIV-1 neutralizing antibody


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 3.00 Å
  • R-Value Free: 0.233 
  • R-Value Work: 0.193 
  • R-Value Observed: 0.195 

wwPDB Validation   3D Report Full Report


This is version 1.2 of the entry. See complete history


Literature

Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies.

Doria-Rose, N.A.Schramm, C.A.Gorman, J.Moore, P.L.Bhiman, J.N.Dekosky, B.J.Ernandes, M.J.Georgiev, I.S.Kim, H.J.Pancera, M.Staupe, R.P.Altae-Tran, H.R.Bailer, R.T.Crooks, E.T.Cupo, A.Druz, A.Garrett, N.J.Hoi, K.H.Kong, R.Louder, M.K.Longo, N.S.McKee, K.Nonyane, M.O'Dell, S.Roark, R.S.Rudicell, R.S.Schmidt, S.D.Sheward, D.J.Soto, C.Wibmer, C.K.Yang, Y.Zhang, Z.Sequencing, Nisc ComparativeMullikin, J.C.Binley, J.M.Sanders, R.W.Wilson, I.A.Moore, J.P.Ward, A.B.Georgiou, G.Williamson, C.Abdool Karim, S.S.Morris, L.Kwong, P.D.Shapiro, L.Mascola, J.R.

(2014) Nature 509: 55-62

  • DOI: 10.1038/nature13036
  • Primary Citation of Related Structures:  
    4ODH, 4OD1, 4OCR, 4OD3, 4OCS, 4OCW, 4ORG

  • PubMed Abstract: 
  • Antibodies capable of neutralizing HIV-1 often target variable regions 1 and 2 (V1V2) of the HIV-1 envelope, but the mechanism of their elicitation has been unclear. Here we define the developmental pathway by which such antibodies are generated and ...

    Antibodies capable of neutralizing HIV-1 often target variable regions 1 and 2 (V1V2) of the HIV-1 envelope, but the mechanism of their elicitation has been unclear. Here we define the developmental pathway by which such antibodies are generated and acquire the requisite molecular characteristics for neutralization. Twelve somatically related neutralizing antibodies (CAP256-VRC26.01-12) were isolated from donor CAP256 (from the Centre for the AIDS Programme of Research in South Africa (CAPRISA)); each antibody contained the protruding tyrosine-sulphated, anionic antigen-binding loop (complementarity-determining region (CDR) H3) characteristic of this category of antibodies. Their unmutated ancestor emerged between weeks 30-38 post-infection with a 35-residue CDR H3, and neutralized the virus that superinfected this individual 15 weeks after initial infection. Improved neutralization breadth and potency occurred by week 59 with modest affinity maturation, and was preceded by extensive diversification of the virus population. HIV-1 V1V2-directed neutralizing antibodies can thus develop relatively rapidly through initial selection of B cells with a long CDR H3, and limited subsequent somatic hypermutation. These data provide important insights relevant to HIV-1 vaccine development.


    Organizational Affiliation

    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA.



Macromolecules
Find similar proteins by:  (by identity cutoff)  |  Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
CAP256-VRC26.06 light chainL214Homo sapiensMutation(s): 0 
Protein Feature View
Expand
  • Reference Sequence
Find similar proteins by:  (by identity cutoff)  |  Structure
Entity ID: 2
MoleculeChainsSequence LengthOrganismDetailsImage
CAP256-VRC26.06 heavy chainH257Homo sapiensMutation(s): 0 
Protein Feature View
Expand
  • Reference Sequence
Small Molecules
Modified Residues  1 Unique
IDChainsTypeFormula2D DiagramParent
TYS
Query on TYS
HL-PEPTIDE LINKINGC9 H11 N O6 STYR
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 3.00 Å
  • R-Value Free: 0.233 
  • R-Value Work: 0.193 
  • R-Value Observed: 0.195 
  • Space Group: H 3 2
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 253.514α = 90
b = 253.514β = 90
c = 70.05γ = 120
Software Package:
Software NamePurpose
SERGUIdata collection
PHASERphasing
PHENIXrefinement
HKL-2000data reduction
HKL-2000data scaling

Structure Validation

View Full Validation Report



Entry History 

Deposition Data

Revision History 

  • Version 1.0: 2014-02-26
    Type: Initial release
  • Version 1.1: 2014-04-02
    Changes: Database references
  • Version 1.2: 2014-05-14
    Changes: Database references